AD109:
A Novel Neuromuscular Approach to Improve Oxygenation
Our investigational oral therapy AD109 is designed to simplify treatment and make it more broadly acceptable to those living with OSA who are untreated and undertreated.
More About AD109
Apnimed:
Innovation in Oxygenation
We discover, develop, and commercialize novel oral therapies that address the underlying neuromuscular dysfunction of sleep-related breathing diseases to help improve oxygenation.
About Apnimed
Our most advanced clinical candidate AD109 is a reflection of our focus on designing solutions that may have potential for sleep apnea patients.
Barry Wohl
Chief Business Officer